112885-42-4

• 常用中文名：枸橼酸莫沙必利
• 常用英文名：Mosapride citrate
• CAS号：112885-42-4
• 分子式：C₂₇H₃₃ClFN₃O₁₀
• 分子量：614.016
• 相关类别： 生物化工 抑制剂 神经信号通路(Neuronal Signaling) 5-HT Receptor 激动剂
• 发布时间：2018-09-25 03:24:12
• 更新时间：2026-07-03 14:13:59
• Mosapride柠檬酸盐是促胃肠动力化合物,是5HT4激动剂。

名称

• 中文名: 4-氨基-5-氯-2-乙氧基-N-[[4-(4-氟苄基)-2-吗啉基]甲基]苯甲酰胺枸橼酸盐
• 英文名: Mosapride citrate
• 中文别名: 枸橼酸莫沙比利; 莫沙必利柠檬酸盐 Solbio/索莱宝 IM1210; 4-氨基-5-氯-2-乙氧基-N-[[4-(4-氟苄基)-2-吗啉基]甲基]苯甲酰胺枸橼酸盐Mosapride citrate; 枸橼酸莫沙必利(MOSAPRIDE CITRATE); 莫沙必利柠檬酸盐,10 MM DMSO 溶液; 柠檬酸莫沙必利; 4-氨基-5-氯-2-乙氧基-N-((4-(4-氟苄基)吗啉-2-基)甲基)苯甲酰胺 2-羟基丙-1,2,3-三羧酸盐; Mosapride citrate 10mg试剂; MOSAPRIDE CITRATE 枸橼酸莫沙必利; Mosapride citrate 10mM * 1mL in DMSO试剂; 4-氨基-5-氯-2-乙氧基-N-[[4-(4-氟苄基)-2; 莫沙必利柠檬酸盐
• 英文别名: TAK-370 citrate; Mosapride CitrateQ: What is Mosapride Citrate Q: What is the CAS Number of Mosapride Citrate Q: What is the storage condition of Mosapride Citrate Q: What e the applications of Mosapride Citrate; 4-amino-5-chloro-2-ethoxy-N-((4-(4-fluorobenzyl)morpholin-2-yl)methyl)benzamide 2-hydroxypropane-1,2,3-tricboxylate; 4-amino-5-chloro-2-ethoxy-N-[[4-[(4-fluorophenyl)methyl]morpholin-2-yl]methyl]benzamide,2-hydroxypropane-1,2,3-tricarboxylic acid; Mosapride Citrate; 4-amino-5-chloro-2-ethoxy-N-[[4-[(4-fluorophenyl)methyl]morpholin-2-yl]methyl]benzamide; Mosapride Citrate DISCONTINUED PLEASE SEE M730995; Mosapride Citrate (TAK-370; 4-Amino-5-chloro-2-ethoxy-N-{[4-(4-fluorobenzyl)morpholin-2-yl]methyl}benzamide 2-hydroxypropane-1,2,3-tricarboxylate (1:1); Mosapride Citrate, 10 mM in DMSO; MOSAPRIDE CITRATE; Benzamide (4-amino-5-chloro-2-ethoxy-N-[[4-[(4-fluorophenyl)methyl]-2-morpholinyl]methyl]; Benzamide, 4-amino-5-chloro-2-ethoxy-N-[[4-[(4-fluorophenyl)methyl]-2-morpholinyl]methyl]-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (salt); enzamidecitrate; Mosapride citrate - Bio-X; (+-)-4-amino-5-chloro-2-ethoxy-n-((4-(4-fluorobenzyl)-2-morpholinyl)methyl)b; Mosapride citrate //BP; Mosapride (citrate); (±)-4-Amino-5-chloro-2-ethoxy-N-((4-(4-fluorobenzyl)-2-morpholinyl)methyl)benzamide Citrate; 4-amino-5-chloro-2-ethoxy-N-{[4-(4-fluorobenzyl)morpholin-2-yl]methyl}benzamide 2-hydroxypropane-1,2,3-tricarboxylate (salt); 4-Amino-5-chloro-2-ethoxy-N-[[4-[(4-fluorophenyl)methyl]-2-morpholinyl]methyl]benzamidecitrate; 4-Amino-5-chloro-2-ethoxy-N-{[4-(4-fluorobenzyl)-2-morpholinyl]methyl}benzamide 2-hydroxy-1,2,3-propanetricarboxylate (1:1); benzamide,4-amino-5-chloro-2-ethoxy-n-((4-((4-fluorophenyl)methyl)-2-morpholin; Mosapridecitrate/TAK-370citrate/AS-4370citrate; 4-Amino-5-chloro-2-ethoxy-N-[[4-[(4-fluorophenyl)methyl]-2-morpholinyl]methyl]-benzamide 2-hydroxy-1,2,3-propanetricboxylate; MFCD00874415; 4-AMINO-5-CHLORO-2-ETHOXY-N-[[4-(4-FLUOROBENZYL)-2-MORPHOLINYL]METHYL]BENZAMIDE CITRATE DIHYDRATE; MOSAPRIDE CITRATE (NON-STERILE BULK FORM); 4-azanyl-5-chloro-2-ethoxy-N-[[4-[(4-fluorophenyl)methyl]morpholin-2-yl]methyl]benzamide; as4370; yl)methyl)-,2-hydroxy-1,2,3-propanetricboxylate(1:1); AS-4370 citrate; UNII:MF497J489P; Mosapride Impurity 2; Benzamide, 4-amino-5-chloro-2-ethoxy-N-[[4-[(4-fluorophenyl)methyl]-2-morpholinyl]methyl]-, 2-hydroxy-1,2,3-propanetricboxylate; Gasmotin

物化性质

• 沸点: 549.2ºC at 760mmHg
• 分子式: C₂₇H₃₃ClFN₃O₁₀
• 分子量: 614.016
• 闪点: 286ºC
• 精确质量: 613.183838
• PSA: 212.44000
• LogP: 2.93620
• 蒸汽压: 4.11E-12mmHg at 25°C
• 储存条件: Desiccate at RT

生物活性

• 描述: Mosapride柠檬酸盐是促胃肠动力化合物,是5HT4激动剂。
• 相关类别:
  信号通路 >> G 蛋白偶联受体/G 蛋白 >> 5-HT受体
  信号通路 >> 神经信号通路 >> 5-HT受体
  研究领域 >> 神经疾病
• 参考文献:

  [1]. Tack J, et al. Systematic review: cardiovascular safety profile of 5-HT(4) agonists developed for gastrointestinal disorders. Aliment Pharmacol Ther. 2012 Apr;35(7):745-67.

  [2]. Curran MP, et al. Mosapride in gastrointestinal disorders. Drugs. 2008;68(7):981-91.

  [3]. Odaka T, et al. Serotonin 5- HT4 receptor agonist (mosapride citrate). Nihon Rinsho. 2006 Aug;64(8):1491-4.

毒性和生态

CHEMICAL IDENTIFICATION RTECS NUMBER : CU9316000 CAS REGISTRY NUMBER : 112885-42-4 LAST UPDATED : 199603 DATA ITEMS CITED : 16 MOLECULAR FORMULA : C21-H25-Cl-F-N3-O3.C6-H8-O7 MOLECULAR WEIGHT : 614.08 HEALTH HAZARD DATA ACUTE TOXICITY DATA TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - rat DOSE/DURATION : >3 gm/kg TOXIC EFFECTS : Sense Organs and Special Senses (Eye) - ptosis Behavioral - convulsions or effect on seizure threshold Gastrointestinal - changes in structure or function of salivary glands REFERENCE : YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 21,3343,1993 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intraperitoneal SPECIES OBSERVED : Rodent - rat DOSE/DURATION : >1 gm/kg TOXIC EFFECTS : Sense Organs and Special Senses (Eye) - lacrimation Behavioral - convulsions or effect on seizure threshold Liver - other changes REFERENCE : YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 21,3343,1993 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Subcutaneous SPECIES OBSERVED : Rodent - rat DOSE/DURATION : >1 gm/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 21,3343,1993 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : >3 gm/kg TOXIC EFFECTS : Behavioral - altered sleep time (including change in righting reflex) Behavioral - convulsions or effect on seizure threshold Lungs, Thorax, or Respiration - respiratory depression REFERENCE : YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 21,3343,1993 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intraperitoneal SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 914 mg/kg TOXIC EFFECTS : Behavioral - altered sleep time (including change in righting reflex) Behavioral - convulsions or effect on seizure threshold Lungs, Thorax, or Respiration - respiratory depression REFERENCE : YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 21,3343,1993 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Subcutaneous SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : >1 gm/kg TOXIC EFFECTS : Behavioral - altered sleep time (including change in righting reflex) Behavioral - convulsions or effect on seizure threshold Lungs, Thorax, or Respiration - respiratory depression REFERENCE : YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 21,3343,1993 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Mammal - dog DOSE/DURATION : >400 mg/kg TOXIC EFFECTS : Gastrointestinal - nausea or vomiting REFERENCE : YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 21,3343,1993 ** OTHER MULTIPLE DOSE TOXICITY DATA ** TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 27 gm/kg/13W-I TOXIC EFFECTS : Liver - changes in liver weight Kidney, Ureter, Bladder - changes in bladder weight Blood - changes in serum composition (e.g. TP, bilirubin, cholesterol) REFERENCE : YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 21,3351,1993 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 9100 mg/kg/26W-I TOXIC EFFECTS : Gastrointestinal - changes in structure or function of salivary glands Blood - changes in serum composition (e.g. TP, bilirubin, cholesterol) Biochemical - Metabolism (Intermediary) - lipids including transport REFERENCE : YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 21,3397,1993 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Mammal - dog DOSE/DURATION : 18200 mg/kg/13W-I TOXIC EFFECTS : Liver - changes in liver weight Endocrine - changes in spleen weight Blood - changes in platelet count REFERENCE : YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 21,3379,1993 ** REPRODUCTIVE DATA ** TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 99 gm/kg SEX/DURATION : male 13 week(s) pre-mating female 2 week(s) pre-mating - 7 day(s) after conception TOXIC EFFECTS : Reproductive - Paternal Effects - other effects on male Reproductive - Maternal Effects - other effects REFERENCE : YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 21,3411,1993 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 330 mg/kg SEX/DURATION : female 7-17 day(s) after conception TOXIC EFFECTS : Reproductive - Maternal Effects - other effects REFERENCE : YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 21,3423,1993 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 7800 mg/kg SEX/DURATION : female 17-21 day(s) after conception lactating female 21 day(s) post-birth TOXIC EFFECTS : Reproductive - Maternal Effects - other effects Reproductive - Effects on Newborn - viability index (e.g., # alive at day 4 per # born alive) Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain) REFERENCE : YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 21,3447,1993 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 7800 mg/kg SEX/DURATION : female 17-21 day(s) after conception lactating female 21 day(s) post-birth TOXIC EFFECTS : Reproductive - Effects on Newborn - behavioral Reproductive - Effects on Newborn - delayed effects REFERENCE : YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 21,3447,1993 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 6500 mg/kg SEX/DURATION : female 6-18 day(s) after conception TOXIC EFFECTS : Reproductive - Fertility - pre-implantation mortality (e.g. reduction in number of implants per female; total number of implants per corpora lutea) REFERENCE : YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 21,3469,1993 TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 3200 mg/kg SEX/DURATION : female 6-18 day(s) after conception TOXIC EFFECTS : Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Effects on Newborn - sex ratio REFERENCE : YACHDS Yakuri to Chiryo. Pharmacology and Therapeutics. (Raifu Saiensu Shuppan K.K., 2-5-13, Yaesu, Chuo-ku, Tokyo 104, Japan) V.1- 1972- Volume(issue)/page/year: 21,3469,1993

安全

• 危害码 (欧洲): Xi

合成路线

112885-41-3 ~86% 112885-42-4

文献：Richter Gedeon Vegyeszeti Gyar RT. Patent: WO2003/106440 A2, 2003 ; Location in patent: Page 10 ;

636582-76-8 ~83% 112885-42-4

文献：Richter Gedeon Vegyeszeti Gyar RT. Patent: WO2003/106440 A2, 2003 ; Location in patent: Page 10 ;

112885-41-3 77-92-9 ~96% 112885-42-4

文献：RANBAXY LABORATORIES LIMITED; HASHMI, Mohd Salman; MADHRA, Mukesh Kumar; IF2 Patent: WO2011/107903 A1, 2011 ; Location in patent: Page/Page column 11 ;

上下游产品

上游产品  2
112885-41-3 77-92-9
下游产品  1
112885-41-3